A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL WITH AN OPEN-LABEL EXTENSION
TO ASSESS THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF EMPAGLIFLOZIN TABLETS IN
PAEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE (EMPA-KIDNEY® KIDS)
- Registry ID
- 1245-0256
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- BOEHRINGER INGELHEIM (CANADA) LTD LTEE
- Start date
- 2026-03-10
- Last update
- 2025-07-30
Conditions
- CHRONIC KIDNEY DISEASE (CKD)
Related clinical trials
- A PHASE IIB, RANDOMISED, MULTICENTRE, DOUBLE-BLIND STUDY TO EVALUATE THE EFFECT OF BAXDROSTAT IN COMBINATION WITH DAPAGLIFLOZIN COMPARED WITH BAXDROSTAT ON ALBUMINURIA IN PARTICIPANTS WITH CHRONIC KIDNEY DISEASE AND HIGH BLOOD PRESSURE
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY
TO INVESTIGATE THE EFFECT OF ORFORGLIPRON ON THE INCIDENCE OF MAJOR ADVERSE
CARDIOVASCULAR EVENTS IN PARTICIPANTS WITH ESTABLISHED ATHEROSCLEROTIC
CARDIOVASCULAR DISEASE AND/OR CHRONIC KIDNEY DISEASE (ATTAIN-OUTCOMES)
- A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF BAXDROSTAT IN COMBINATION WITH DAPAGLIFLOZIN COMPARED WITH DAPAGLIFLOZIN ALONE ON RENAL OUTCOMES AND CARDIOVASCULAR MORTALITY IN PARTICIPANTS WITH CHRONIC KIDNEY DISEASE AND HIGH BLOOD PRESSURE (BAXDUO-PACIFIC)
- STUDIES OF HEART & KIDNEY PROTECTION WITH BI 690517 IN COMBINATION WITH
EMPAGLIFLOZIN: A MULTICENTER, INTERNATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF THE ALDOSTERONE SYNTHASE INHIBITOR BI 690517 IN
COMBINATION WITH EMPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE
- AN 18-MONTH, OPEN-LABEL, SINGLE-ARM SAFETY EXTENSION STUDY OF AN AGE- AND BODYWEIGHT-ADJUSTED ORAL FINERENONE REGIMEN, IN ADDITION TO AN ACEI OR ARB, FOR THE TREATMENT OF CHILDREN AND YOUNG ADULTS FROM 1 TO 18 YEARS OF AGE WITH CHRONIC KIDNEY DISEASE AND PROTEINURIA
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE
THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND MAJOR
ADVERSE KIDNEY EVENTS IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN OR EQUAL TO 27 KG/M2 AND ATHEROSCLEROTIC
CARDIOVASCULAR DISEASE AND/OR CHRONIC KIDNEY DISEASE
View on source registry